Bethesda, Md. — October 16, 2025 — Leads & Copy — Gain Therapeutics, Inc. (Nasdaq: GANX) will participate in the 2025 Maxim Growth Summit from October 22nd to 23rd at The Hard Rock Hotel NYC. Gene Mack, President and CEO of Gain, will be part of a live discussion on neurodegenerative diseases on October 22nd.
The summit brings together industry leaders and innovators to explore trends and advancements. Keynote speakers include Larry Kudlow and Christopher Ruddy. The conference features roundtable discussions with CEOs from small and mid-cap companies, covering sectors such as biotechnology, AI, energy, and more.
Gain Therapeutics is a clinical-stage biotechnology company focused on allosteric therapies. Their lead drug candidate, GT-02287, is in a Phase 1b clinical trial for Parkinson’s disease. It also shows potential for Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. The company uses its Magellan™ platform to discover novel treatments for disorders including neurodegenerative diseases and oncology.
Apaar Jammu, Manager, Investor Relations and Public Relations, ajammu@gaintherapeutics.com
Chuck Padala, Managing Director, chuck@lifesciadvisors.com
Nic Johnson, nic.johnson@russopartnersllc.com, (760) 846-9256
Elio Ambrosio, elio.ambrosio@russopartnersllc.com, (760) 846-9256
Source: Gain Therapeutics, Inc.
